| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 19157 |
| Title of Study | AURIGA/An observational study program to investigate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting. |
| Primary Objective | The primary objective of this study was to evaluate the effectiveness based on change in VA of intravitreal aflibercept in DME and/or macular edema secondary to RVO in routine clinical practice in each of the participating countries by cohort after 12 months. |
| Number of Sites | 14 |
| Period of Study | From：2017 Q4 to：2022 Q3 |
| Number of Patients | 421人 |
| IRB Approval Date | 25 Jun,2018 Taipei Veterans General Hospital 10 Sep,2018 National Taiwan University Hospital 18 Sep,2018 MacKay Memorial Hospital 18 Sep,2018 Changhua Christian Hospital 19 Sep,2018 Shin Kong Wu Ho-Su Memorial Hospital 02 Oct,2018 China Medical University Hospital 02 Oct,2018 National Cheng Kung University Hospital 03 Oct,2018 Kaohsiung Veterans General Hospital 22 Nov,2018 Chi Mei Medical Center 18 Dec,2018 Kaohsiung Medical University Chung-Ho Memorial Hospital 06 Sep,2019 Tri-Service General Hospital 10 Mar,2020 Hualien Tzu Chi Hospital 18 Mar,2020 Taipei Municipal Wanfang Hospital 12 Jun,2020 Far Eastern Memorial Hospital |
| Publication Plan / Date | Unknown |
